PharmaBlock Sciences (Nanjing), Inc. (SHE:300725)
China
· Delayed Price · Currency is CNY 32.06
-0.23 (-0.71%)
May 15, 2025, 3:04 PM CST
SHE:300725 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 1,689 | 1,725 | 1,594 | 1,201 | 1,022 | Upgrade
|
Other Revenue | - | 0.45 | 0.49 | 0.36 | 0.13 | Upgrade
|
| Revenue | 1,689 | 1,725 | 1,595 | 1,202 | 1,022 | Upgrade
|
Revenue Growth (YoY) | -2.12% | 8.18% | 32.71% | 17.55% | 54.36% | Upgrade
|
Cost of Revenue | 1,046 | 1,018 | 878.71 | 632.85 | 556.44 | Upgrade
|
Gross Profit | 642.61 | 707.2 | 715.99 | 568.78 | 465.79 | Upgrade
|
Selling, General & Admin | 238.47 | 253.44 | 248.49 | 174.63 | 151.83 | Upgrade
|
Research & Development | 107.33 | 169.17 | 168.32 | 114.02 | 90.93 | Upgrade
|
Other Operating Expenses | -3.7 | 14.8 | 11.89 | 8.28 | 6.37 | Upgrade
|
Operating Expenses | 342.1 | 447.36 | 435.78 | 299.34 | 253.98 | Upgrade
|
Operating Income | 300.51 | 259.84 | 280.21 | 269.44 | 211.81 | Upgrade
|
Interest Expense | - | -66.1 | -45.72 | -9.18 | -0.63 | Upgrade
|
Interest & Investment Income | 35.44 | 24.79 | 26.7 | 249.42 | 6.67 | Upgrade
|
Currency Exchange Gain (Loss) | - | 0.46 | 34.45 | -16.92 | -23.64 | Upgrade
|
Other Non Operating Income (Expenses) | -36.1 | -2.1 | -0.92 | 13.47 | -0.08 | Upgrade
|
EBT Excluding Unusual Items | 299.85 | 216.89 | 294.72 | 506.23 | 194.13 | Upgrade
|
Gain (Loss) on Sale of Investments | 9.36 | -21.33 | 1.99 | 1.67 | - | Upgrade
|
Gain (Loss) on Sale of Assets | - | 0.42 | - | 0.04 | - | Upgrade
|
Asset Writedown | -60.31 | -14.8 | -4.38 | -0.17 | -0.18 | Upgrade
|
Other Unusual Items | - | 40.19 | 30.94 | - | 10.56 | Upgrade
|
Pretax Income | 248.9 | 221.38 | 323.26 | 507.77 | 204.5 | Upgrade
|
Income Tax Expense | 29.36 | 24.01 | -2.63 | 4 | 20.3 | Upgrade
|
Earnings From Continuing Operations | 219.54 | 197.36 | 325.89 | 503.77 | 184.2 | Upgrade
|
Minority Interest in Earnings | - | 0 | -11.67 | -17.21 | 0 | Upgrade
|
Net Income | 219.54 | 197.36 | 314.22 | 486.56 | 184.21 | Upgrade
|
Net Income to Common | 219.54 | 197.36 | 314.22 | 486.56 | 184.21 | Upgrade
|
Net Income Growth | 11.24% | -37.19% | -35.42% | 164.14% | 21.13% | Upgrade
|
Shares Outstanding (Basic) | 200 | 199 | 199 | 198 | 186 | Upgrade
|
Shares Outstanding (Diluted) | 200 | 201 | 200 | 199 | 188 | Upgrade
|
Shares Change (YoY) | -0.90% | 0.62% | 0.37% | 6.09% | 0.79% | Upgrade
|
EPS (Basic) | 1.10 | 0.99 | 1.58 | 2.46 | 0.99 | Upgrade
|
EPS (Diluted) | 1.10 | 0.98 | 1.57 | 2.44 | 0.98 | Upgrade
|
EPS Growth | 12.25% | -37.58% | -35.66% | 148.98% | 20.19% | Upgrade
|
Free Cash Flow | 184.7 | -68.93 | -311.3 | -267.73 | 196.33 | Upgrade
|
Free Cash Flow Per Share | 0.93 | -0.34 | -1.55 | -1.34 | 1.04 | Upgrade
|
Dividend Per Share | - | 0.310 | 0.100 | 0.100 | 0.077 | Upgrade
|
Dividend Growth | - | 210.00% | - | 30.04% | -33.36% | Upgrade
|
Gross Margin | 38.05% | 40.99% | 44.90% | 47.33% | 45.57% | Upgrade
|
Operating Margin | 17.80% | 15.06% | 17.57% | 22.42% | 20.72% | Upgrade
|
Profit Margin | 13.00% | 11.44% | 19.70% | 40.49% | 18.02% | Upgrade
|
Free Cash Flow Margin | 10.94% | -4.00% | -19.52% | -22.28% | 19.21% | Upgrade
|
EBITDA | 431.29 | 372.62 | 366.45 | 322.64 | 236.28 | Upgrade
|
EBITDA Margin | 25.54% | 21.60% | 22.98% | 26.85% | 23.11% | Upgrade
|
D&A For EBITDA | 130.78 | 112.78 | 86.24 | 53.2 | 24.47 | Upgrade
|
EBIT | 300.51 | 259.84 | 280.21 | 269.44 | 211.81 | Upgrade
|
EBIT Margin | 17.80% | 15.06% | 17.57% | 22.42% | 20.72% | Upgrade
|
Effective Tax Rate | 11.79% | 10.85% | - | 0.79% | 9.93% | Upgrade
|
Revenue as Reported | - | 1,725 | 1,595 | 1,202 | 1,022 | Upgrade
|
Advertising Expenses | - | 1.93 | 0.93 | 0.6 | 0.76 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.